Operating Lease, Right-of-Use Asset of Gain Therapeutics, Inc. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Gain Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • Gain Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $184,422, a 35% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Gain Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $184,422 -$97,156 -35% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $233,200 -$92,679 -28% 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $183,664 -$200,482 -52% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $219,715 -$239,500 -52% 31 Dec 2024 10-Q 12 Nov 2025 2025 Q3
Q3 2024 $281,578 -$209,181 -43% 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $325,879 -$233,892 -42% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $384,146 -$225,731 -37% 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $459,215 -$200,718 -30% 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $490,759 -$179,502 -27% 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $559,771 -$186,113 -25% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $609,877 -$221,352 -27% 31 Mar 2023 10-Q 12 May 2023 2023 Q1
Q4 2022 $659,933 -$241,109 -27% 31 Dec 2022 10-K 26 Mar 2024 2023 FY
Q3 2022 $670,261 -$77,268 -10% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $745,884 -$66,526 -8.2% 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 $831,229 +$332,212 +67% 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q4 2021 $901,042 +$377,962 +72% 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $747,529 30 Sep 2021 10-Q 12 Nov 2021 2021 Q3
Q2 2021 $812,410 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 $499,017 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $523,080 31 Dec 2020 10-K 25 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.